Bluefin Capital Management’s Amgen AMGN Stock Holding History

Bluefin Capital Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,400	Closed	-$20K	–	512
2019 Q2	$20K	Buy	+10,400	New	+$1.86M	﹤0.01%	287

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bluefin Capital Management's AMGN Position: Q1 2026 in Review

Bluefin Capital Management sold out of Amgen (AMGN) in Q1 2026, closing a stake of 3,800 shares — an estimated $1.24M sold.

Bluefin Capital Management first reported a position in AMGN in Q2 2013 and held it in 22 quarters. The position peaked at $4.04M in Q4 2014. 3,132 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

Bluefin Capital Management reported no remaining Amgen position as of Q1 2026 after selling out during the quarter.
Bluefin Capital Management sold 3,800 Amgen shares in Q1 2026, an estimated $1.24M.
Bluefin Capital Management first reported a position in Amgen in Q2 2013 and held it in 22 quarters.
Bluefin Capital Management's Amgen position peaked at $4.04M in Q4 2014.
3,132 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Bluefin Capital Management's 13F filing for Q1 2026, filed 15 May 2026.